Severe drug interaction alerts flood ICU care in elderly patients

This single-center analysis quantifies how often Lexi-Interact category D and X alerts occur in a predominantly elderly ICU population and identifies treatment intensity, not baseline frailty markers, as the dominant driver.

📅 Journal publication: Oct 9, 2026 · Last updated: Oct 9, 2026

butorphanoldexmedetomidinemidazolampropofolnoscapinechlorphenamineclopidogrelspironolactonedrug-drug interactionsLexi-Interactintensive care unitpolypharmacyCNS depressionmedication safetypharmacoepidemiologyretrospective cohortgeriatric pharmacy Geriatrics / Geriatric Pharmacy

Also in Medication Safety, Critical Care / ICU

Background Information

ICU patients face frequent severe drug interactions from sedative combinations.

Severe potential drug-drug interactions (pDDIs) are common in ICU settings, posing significant risks to patient safety. The study found 65.73% of ICU patients experienced severe pDDIs, mostly involving sedative-analgesic combinations leading to central nervous system depression. Although impactful, findings from this single-center study may not generalize across all healthcare settings; pharmacist involvement is crucial for managing high-risk medications. Pharmacists should enhance vigilance for sedative-analgesic drug interactions in ICU patients to prevent severe pDDIs.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

View on PubMed →

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →